Bdexipime-T 1.125 Injection 1's belongs to the class of medications called ‘antibiotics’ used to treat bacterial infections. Bacterial infections are caused by the multiplication of harmful bacteria inside or on the body. These harmful bacteria produce chemicals known as toxins, which can damage tissue and make you sick. Symptoms of bacterial infection vary depending on the organ affected by bacteria.

Bdexipime-T 1.125 Injection 1's is a combination of two medicines: Cefepime and Tazobactam. Cefepime is a cephalosporin antibiotic. It has bactericidal action (kills bacteria). It works by preventing the formation of the cell wall (the outer protective layer of bacteria, which is essential for its survival) by preventing protein synthesis. Tazobactam is a beta-lactamase inhibitor. It can improve the spectrum of antibacterial action by inhibiting the action of beta-lactamase. Beta-lactamase is an enzyme produced by bacteria that can destroy antibiotics (cefotaxime). Bdexipime-T 1.125 Injection 1's is only used to treat bacterial infections and is not recommended for viral infections.

 Bdexipime-T 1.125 Injection 1's will be administered by a healthcare professional; do not self-administer. The common side effects of Bdexipime-T 1.125 Injection 1's are pain and swelling at the injection site and skin rash. These side effects are usually mild and temporary. However, if any of these side effects persist or get worse, inform your doctor immediately.

It is not recommended to take Bdexipime-T 1.125 Injection 1's if you are allergic to penicillin, any cephalosporin antibiotic, or its contents. Before taking Bdexipime-T 1.125 Injection 1's, inform your doctor if you have kidney problems, diabetes, gastrointestinal problems, especially colitis (inflammation of the large intestine), or use other antibiotics. Do not discontinue or abruptly stop using Bdexipime-T 1.125 Injection 1's as it may lead to antibiotic resistance (bacteria become resistant to antibiotics). This medicine is not recommended in children aged less than two years. Bdexipime-T 1.125 Injection 1's should be used with caution in pregnant women, breastfeeding mothers and elderly people. Bdexipime-T 1.125 Injection 1's may interact with alcohol. Bdexipime-T 1.125 Injection 1's may not affect your ability to drive.

Bdexipime-T 1.125 Injection 1's is used in the treatment of various moderate to severe bacterial infections. The detailed uses of Bdexipime-T 1.125 Injection 1's are as follows:

• Urinary Tract Infections (UTIs): Bdexipime-T 1.125 Injection 1's is effective against uncomplicated and complicated UTIs affecting the bladder (cystitis), ureter (ureteritis), and kidneys (pyelonephritis).
• Skin and Soft Tissue Infections: Bdexipime-T 1.125 Injection 1's is used to treat bacterial infections of the skin and underlying tissues, such as wounds, abscesses, and cellulitis.
• Intra-abdominal Infections: Bdexipime-T 1.125 Injection 1's helps in treating infections within the abdominal cavity, such as peritonitis and abdominal abscesses.
• Lower Respiratory Tract Infections: Bdexipime-T 1.125 Injection 1's is used to treat infections in the airways (bronchitis) and lungs (pneumonia) caused by susceptible bacteria.
• Bloodstream Infections: Bdexipime-T 1.125 Injection 1's is effective in treating sepsis, particularly caused by gram-negative bacteria.
• Empiric Therapy in Febrile Neutropenia: Bdexipime-T 1.125 Injection 1's is given as a first-line treatment in patients with a low neutrophil count and fever (febrile neutropenia), particularly those undergoing chemotherapy.

• Follow your doctor's instructions on the dosage and timing of this medication.
• Bdexipime-T 1.125 Injection 1's will be administered by the doctor or nurse in a healthcare setting.
• Do not self-administer.

Bdexipime-T 1.125 Injection 1's contains Cefepime and Tazobactam. Cefepime is a cephalosporin antibiotic, whereas Tazobactam is a beta-lactamase inhibitor. Bdexipime-T 1.125 Injection 1's has broad-spectrum activity and is effective against both gram-positive and gram-negative bacteria. It makes the drug effective in multiple moderate to severe bacterial infections such as urinary tract infections (UTI), skin infections, intra-abdominal infections, lower respiratory tract (lung) infections such pneumonia (inflammation of the air sacs present in lungs) and bronchitis (inflammation of the bronchi), septicemia (including infections of the bloodstream), and empiric treatment in febrile neutropenic patients (development of fever in patients with low neutrophil count).

Bdexipime-T 1.125 Injection 1's should be used with caution in patients with kidney impairment. There is a risk of serious adverse events such as confusion, hallucinations, stupor (a state of near-unconsciousness), and seizures (fits). Bdexipime-T 1.125 Injection 1's may cause Clostridium difficile-associated diarrhoea (CDAD), ranging from mild diarrhea to fatal colitis (inflammation of the large intestine). If CDAD is suspected or confirmed, the doctor may discontinue therapy and advise appropriate fluid and electrolyte management, protein supplementation, and antibiotic therapy to treat CDAD. A Bdexipime-T 1.125 Injection 1's may cause positive direct Coomb’s test, which indicates antibodies against red blood cells. So, it is necessary to let your doctor know that you are taking this medicine before undergoing laboratory tests. Do not discontinue or abruptly stop the medication as it may lead to antibiotic resistance, a condition in which bacteria become resistant to antibiotics. Bdexipime-T 1.125 Injection 1's may cause superinfection (additional infection caused by other microbes) on prolonged use.